Premium
Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach–Merritt phenomenon
Author(s) -
Chiu Yvonne E.,
Drolet Beth A.,
Blei Francine,
Carcao Manuel,
Fangusaro Jason,
Kelly Michael E.,
Krol Alfons,
Lofgren Sabra,
Mancini Anthony J.,
Metry Denise W.,
Recht Michael,
Silverman Robert A.,
Tom Wynnis L.,
Pope Elena
Publication year - 2012
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24103
Subject(s) - medicine , propranolol , kasabach–merritt syndrome , hemangioendothelioma , hemangioma , angioma , dermatology , surgery , pathology , vascular disease
Propranolol is a non‐selective beta‐adrenergic antagonist successfully used in a case of kaposiform hemangioendothelioma (KHE) associated with Kasabach–Merritt phenomenon (KMP). We report 11 patients treated with propranolol for KHE and the related variant tufted angioma (TA), six of whom also had KMP. The varied responses to treatment, with only 36% responding in our series, demonstrate the need for further study of this medication before routine use for these indications. Pediatr Blood Cancer 2012; 59: 934–938. © 2012 Wiley Periodicals, Inc.